Boditech Med Inc. (KOSDAQ:206640)
9,750.00
+50.00 (0.52%)
Oct 2, 2026, 3:30 PM KST
Boditech Med Revenue
Boditech Med had revenue of 50.42B KRW in the quarter ending June 30, 2026, with 21.54% growth. This brings the company's revenue in the last twelve months to 174.78B, up 16.99% year-over-year. In the year 2025, Boditech Med had annual revenue of 162.09B with 17.32% growth.
Revenue (ttm)
174.78B
Revenue Growth
+16.99%
P/S Ratio
1.20
Revenue / Employee
323.06M
Employees
541
Market Cap
210.57B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 162.09B | 23.93B | 17.32% |
| Dec 31, 2024 | 138.16B | 3.94B | 2.94% |
| Dec 31, 2023 | 134.22B | 16.14B | 13.67% |
| Dec 31, 2022 | 118.08B | -39.63B | -25.13% |
| Dec 31, 2021 | 157.71B | 13.58B | 9.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Value Added Technology | 441.04B |
| Vieworks | 244.28B |
| Dongbang Medical | 125.12B |
| Shinhung | 105.89B |
| Bio Plus | 99.15B |
| Curexo | 77.74B |
| JETEMA, | 76.58B |
| T&R Biofab | 32.73B |